Literature DB >> 15802719

Recent developments in bisphosphonates for patients with metastatic breast cancer.

Mary C Gainford1, George Dranitsaris, Mark Clemons.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15802719      PMCID： PMC555882          DOI： 10.1136/bmj.330.7494.769

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  27 in total

Review 1.  Should oral bisphosphonates be standard of care in women with early breast cancer?

Authors:  Mark Clemons; Sunil Verma
Journal:  Breast Cancer Res Treat       Date:  2005-04       Impact factor: 4.872

2.  Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis.

Authors:  B E Hillner; J C Weeks; C E Desch; T J Smith
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

3.  [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].

Authors:  M Tubiana-Hulin; P Beuzeboc; L Mauriac; N Barbet; M Frenay; A Monnier; J M Pion; O Switsers; J L Misset; S Assadourian; E Bessa
Journal:  Bull Cancer       Date:  2001-07       Impact factor: 1.276

Review 4.  Analysis of skeletal-related events in breast cancer and response to therapy.

Authors:  P LoRusso
Journal:  Semin Oncol       Date:  2001-08       Impact factor: 4.929

5.  Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.

Authors:  A Lipton; R L Theriault; G N Hortobagyi; J Simeone; R D Knight; K Mellars; D J Reitsma; M Heffernan; J J Seaman
Journal:  Cancer       Date:  2000-03-01       Impact factor: 6.860

Review 6.  Bisphosphonates for the relief of pain secondary to bone metastases.

Authors:  R Wong; P J Wiffen
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 7.  Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer.

Authors:  J R Ross; Y Saunders; P M Edmonds; S Patel; K E Broadley; S R D Johnston
Journal:  BMJ       Date:  2003-08-30

8.  Risk of complications from bone metastases in breast cancer. implications for management.

Authors:  T A Plunkett; P Smith; R D Rubens
Journal:  Eur J Cancer       Date:  2000-03       Impact factor: 9.162

Review 9.  Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.

Authors:  Pierre P Major; Richard Cook
Journal:  Am J Clin Oncol       Date:  2002-12       Impact factor: 2.339

10.  Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

Authors:  J-J Body; I J Diel; M R Lichinitser; E D Kreuser; W Dornoff; V A Gorbunova; M Budde; B Bergström
Journal:  Ann Oncol       Date:  2003-09       Impact factor: 32.976
View more
  12 in total

Review 1.  Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer.

Authors:  Paul L McCormack; Greg L Plosker
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.

Authors:  Ingo J Diel; Andreas H A Kurth; Hans-Bernd Sittig; Harald Meden; Michael Maasberg; Andreas Sandermann; Raoul Bergner
Journal:  Support Care Cancer       Date:  2010-02-12       Impact factor: 3.603

Review 3.  Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists.

Authors:  Nathaniel Bouganim; George Dranitsaris; Eitan Amir; Mark Clemons
Journal:  Support Care Cancer       Date:  2011-07-22       Impact factor: 3.603

4.  Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.

Authors:  J D Veltman; M E H Lambers; M van Nimwegen; R W Hendriks; H C Hoogsteden; J P J J Hegmans; J G J V Aerts
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

5.  Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.

Authors:  Mateya Trinkaus; Christine Simmons; Jeff Myers; George Dranatisaris; Mark Clemons
Journal:  Support Care Cancer       Date:  2009-05-08       Impact factor: 3.603

6.  Automated CT-based analysis to detect changes in the prevalence of lytic bone metastases from breast cancer.

Authors:  T Skrinskas; M Clemons; O Freedman; I Weller; C M Whyne
Journal:  Clin Exp Metastasis       Date:  2008-10-22       Impact factor: 5.150

7.  Image-guided cryoablation for the treatment of painful musculoskeletal metastatic disease: a single-center experience.

Authors:  J David Prologo; Matthew Passalacqua; Indravadan Patel; Nathan Bohnert; David J Corn
Journal:  Skeletal Radiol       Date:  2014-06-28       Impact factor: 2.199

8.  Comparing the results of bisphosphonate use in clinical trials with actual practice: a case of apples and oranges?

Authors:  M C Gainford; G Dranitsaris; W Ooi; M Vanhuyse; M Clemons
Journal:  Curr Oncol       Date:  2006-10       Impact factor: 3.677

9.  A primer of bone metastases management in breast cancer patients.

Authors:  B Petrut; M Trinkaus; C Simmons; M Clemons
Journal:  Curr Oncol       Date:  2008-01       Impact factor: 3.677

10.  Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.

Authors:  Christina L Addison; Gregory R Pond; Brandy Cochrane; Huijun Zhao; Stephen K Chia; Mark N Levine; Mark Clemons
Journal:  J Bone Oncol       Date:  2015-06-12       Impact factor: 4.072
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.